



ASX ANNOUNCEMENT

Doctors on Demand Surpasses 1 Million Consultations and Delivers Sustained Profitability through Record Revenue Growth

21 APRIL 2026

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and the Company**), a leading digital health platform business, provides an update on the performance of its Doctors on Demand (DoD) telehealth business, following continued growth in revenue, consultation volumes, and the achievement of sustained EBITDA profitability since acquisition.

Doctors on Demand has now completed over 1 million consultations since the start of FY2024, a key milestone that demonstrates the scale, high utilisation, and operating leverage of the platform and business model. Acquired in October 2023 (FY2024), DoD is Vitura's 24/7 virtual GP primary care telehealth service. It allows patients to speak face-to-face via video with a doctor online about general health concerns or queries, diagnoses, or monitoring from preventative care through to chronic conditions.

At the time of acquisition Doctors on Demand recorded revenue of \$14.1 million for the first three quarters of FY2024. Over the same period in FY2026 revenue increased to 21.6 million, a 54% uplift over two years, reflecting strong underlying demand and Vitura's integration and execution capabilities.*

This growth has been driven by Vitura's disciplined integration and operational focus, together with execution of its growth strategy that leverages the expanding Australian telehealth market.

Importantly, operational expenditure has been reduced by 4% compared. This has resulted in a 14% improvement in efficiency, and along with the strong revenue growth and relatively consistent gross margins, has enabled DoD to successfully transition into sustainable EBITDA profitability. This is demonstrated with EBITDA margin improvement from FY2024 to FY2026 moving from negative 3% to 5% over the respective periods. Based on trading performance to date and current operating conditions, Vitura expects DoD to continue to grow into FY2027 at both revenue and EBITDA lines, supporting the potential for another full-year record.

The number of qualified and vetted doctors on the platform has also increased from approximately 200 at acquisition to over 320 as at 20 April 2026, who use DoD as both a primary and secondary source of income.** This shows both an increase in retention and usage by the existing doctor cohort, as well as new doctors being consistently onboarded as the number of patients and consultations scales.

As the shift continues towards the convenience and quality of Telehealth providers in Australia, Doctors on Demand is positioned well to capture further market share across its product and service offerings. And with Vitura's aim to further integrate and extend the product and service offerings by connecting its General and Specialty Clinic B2C patient base, there is the expectation of further financial realisation through FY2027.

Key Performance Metrics**

	Revenue	Patient Consults	Daily Consult Record
FY2024 Q1-Q3	\$14.1m	210,518	1,039
FY2025 Q1-Q3	\$18.4m	271,385	1,456
FY2026 Q1-Q3	\$21.6m	311,152	1,539

Vitura Chief Revenue Officer Ryan Tattle said:

“When Vitura completed the acquisition of Doctors on Demand in October 2023, the expectation was that it would be cash flow positive at completion with the aim to produce profitability soon after. We have achieved this and gone beyond, with DoD delivering positive operating cash flow and EBITDA during the first three quarters of FY2026. This is a meaningful outcome for both DoD and Vitura and reflects the discipline and capability of the team that has driven these record results.”

“The gross margin profile of DoD is relatively stable and predictable, which makes DoD an increasingly important contributor to Vitura’s overall revenue and profit diversification. We have a mix of B2C and B2B patients, including consultations driven directly by private health insurers to Doctors on Demand which can also provide further sustainability.”

* All financial figures are unaudited and prepared on a consistent basis with prior disclosures unless otherwise stated. FY2026 numbers are audited up to H1.

** Source: Doctors on Demand.

ENDS

Authorised by – The Board of Vitura Health Limited.

Contact

Vitura Health Limited

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company’s expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements

are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.candor.com.au
The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.
- www.releaf.com.au
The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.